Datasets

Clinical data from patients with cerebral tumors of WHO grade II and III

Contributors
Weller M
Weber RG
Willscher E
Riehmer V
Hentschel B
Kreuz M
Felsberg J
Beyer U
Löffler-Wirth H
Kaulich K
Steinbach JP
Hartmann C
Gramatzki D
Schramm J
Westphal M
Schackert G
Simon M
Martens T
Boström J
Hagel C
Sabel M
Krex D
Tonn JC
Wick W
Noell S
Schlegel U
Radlwimmer B
Pietsch T
Loeffler M
von Deimling A
Binder H
Reifenberger G
Progression free and overall survival of patients with gliomas dependent on molecular profiles

Clinical data from patients with glioblastoma

Contributors
Weller M
Felsberg J
Hartmann C
Berger H
Steinbach JP
Schramm J
Westphal M
Schackert G
Simon M
Tonn JC
Heese O
Krex D
Nikkhah G
Pietsch T
Wiestler O
Reifenberger G
von Deimling A
Loeffler M
Progression free survival and overall survival of patients with glioblastoma dependent on TP53 mutation, p53 immunoreactivity, epidermal growth factor receptor, cyclin-dependent kinase CDK 4 or murine double minute 2 amplification, CDKN2A homozygous deletion, allelic losses on chromosome arms 1p, 9p, 10q, and 19q, O6-methylguanine methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutations

Clinical data from patients with untreated aggressive Non-Hodgkin's-Lymphoma aged
61-80 years without relevant concomittant diseases

Contributors
Pfreundschuh M
Schubert J
Ziepert M
Schmits R
Mohren M
Lengfelder E
Reiser M
Nickenig C
Clemens M
Peter N
Bokemeyer C
Eimermacher H
Ho A
Hoffmann M
Mertelsmann R
Trümper L
Balleisen L
Liersch R
Metzner B
Hartmann F
Glass B
Poeschel V
Schmitz N
Ruebe C
Feller AC
Loeffler M
German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
complete clinical data set for the clinical trial

Clinical data from patients with untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma aged 18-60 years

Contributors
Pfreundschuh M
Trümper L
Osterborg A
Pettengell R
Trneny M
Imrie K
Ma D
Gill D
Walewski J
Zinzani PL
Stahel R
Kvaloy S
Shpilberg O
Jaeger U
Hansen M
Lehtinen T
López-Guillermo A
Corrado C
Scheliga A
Milpied N
Mendila M
Rashford M
Kuhnt E
Loeffler M
MabThera International Trial Group
complete clinical data set for the clinical trial

Clinical data from patients with untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma aged 18-60 years

Contributors
Pfreundschuh M
Kuhnt E
Trümper L
Osterborg A
Trneny M
Shepherd L
Gill DS
Walewski J
Pettengell R
Jaeger U
Zinzani PL
Shpilberg O
Kvaloy S
de Nully Brown P
Stahel R
Milpied N
López-Guillermo A
Poeschel V
Grass S
Loeffler M
Murawski N
MabThera International Trial (MInT) Group
complete clinical data set for the clinical trial

Expression data from cerebral tumors of WHO grade II and III

Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed microarray-based genome- and transcriptome-wide molecular profiling of primary tumor samples from 137 patients with cerebral gliomas, 61 WHO grade II and 76 WHO grade III tumors.

Expression data from cerebral tumors of WHO grade II and III

Contributors
Weller M
Weber RG
Willscher E
Riehmer V
Hentschel B
Kreuz M
Felsberg J
Beyer U
Löffler-Wirth H
Kaulich K
Steinbach JP
Hartmann C
Gramatzki D
Schramm J
Westphal M
Schackert G
Simon M
Martens T
Boström J
Hagel C
Sabel M
Krex D
Tonn JC
Wick W
Noell S
Schlegel U
Radlwimmer B
Pietsch T
Loeffler M
von Deimling A
Binder H
Reifenberger G
Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed microarray-based genome- and transcriptome-wide molecular profiling of primary tumor samples from 137 patients with cerebral gliomas, 61 WHO grade II and 76 WHO grade III tumors.